Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SomaLogic and Otsuka Pharmaceutical have entered into a collaboration agreement to use SomaLogic's proprietary aptamer technology to discover and develop novel diagnostic products and to design research tools that will enhance Otsuka's pharmaceutical discovery and development efforts.
Subscribe to our email newsletter
Under the terms of the agreement, SomaLogic will receive committed research funding and will be entitled to receive a royalty on any marketed products developed as a result of the collaboration. Otsuka also received an option to acquire distribution rights in Asia for certain SomaLogic clinical diagnostics products. In addition, SomaLogic received an equity investment from Otsuka.
SomaLogic has generated novel aptamers that target over 500 human proteins. As part of this collaboration, Otsuka will have access to this growing resource for target validation, drug screening and other assays to accelerate their development of new therapeutics. In addition, Otsuka will have access to SomaLogic’s highly multiplexed proteomic arrays to facilitate the discovery and monitoring of biomarkers in support of Otsuka’s clinical programs and therapeutic products.
Larry Gold, CEO of SomaLogic, said: “Otsuka’s broad vision for global healthcare will help us achieve our goal of using aptamer technology to transform medicine.”